HYTN Receives Initial International Purchase GMP Vape Cartridges
Source: HYTN Innovations Inc.
June 11, 2025 08:00 ET
HYTN Receives Initial
International Purchase Order
for GMP Vape Cartridges
VANCOUVER, British Columbia, June 11, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE:
HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a leader in pharmaceutical-grade
cannabis manufacturing, is pleased to announce that it has received its rst purchase order and
import permit for Good Manufacturing Practices (GMP) cannabis vape cartridges (the “Products” or
“Vapes”). This milestone follows the Company’s January 21 news release detailing a collaboration
agreement with SNDL to develop GMP-compliant vape cartridges.
The initial order, received June 6, 2025, calls for 1000 one-gram live resin vape cartridges, which
HYTN will manufacture in strict compliance with GMP standards and export under its Drug
Establishment Licence (DEL) to the United Kingdom, pending export permit approval, with
shipment scheduled to occur before the import permit expiry date of September 6, 2025. This
underscores HYTN’s commitment to quality, safety, and consistency in its pharmaceutical-grade
cannabis offerings and highlights its capability to service regulated international markets.
“We’re excited to see demand for our GMP-compliant vape cartridges,” said Jason Broome, HYTN
COO. “International drug development requires specialized and validated facilities, equipment, and
systems. HYTN’s capabilities meet these stringent requirements. This order represents the broader
opportunities for alternative dosing formats in global pharmaceutical cannabis markets, and we
look forward to continuing to explore the market demand for these products.”
By broadening its product portfolio and deepening its commitment to next-generation cannabis
pharmaceuticals, HYTN continues to demonstrate its position as a trusted partner for international
clients seeking high-quality GMP cannabis products.
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical company specializing in the formulation, manufacturing,
marketing, and sale of products containing psychoactive and psychotropic compounds, including
cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming
a premier provider of these products across all federally regulated markets. The Company
accomplishes this by strategically identifying market opportunities and effectively bringing
innovative products to market through its advanced development platform.
About Good Manufacturing Practices (GMP)
GMP guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that
a manufactured product is safe for human consumption or use. Many countries have legislated that
manufacturers follow GMP procedures and create their own GMP guidelines that correspond with
their legislation.
For more information contact:
Elliot McKerr
Chief Executive Ofcer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
Forward-Looking Statements Disclaimer
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents
of this press release.
Certain information contained herein may constitute forward-looking information that involves
risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking
statements, including, but not limited to, statements regarding anticipated timelines for regulatory
approvals, shipment schedules, receipt of additional purchase orders, the Company’s ability to fulll
such orders, its capacity to maintain compliance with GMP standards and DEL requirements, its
ability to export products internationally, and the success of its ongoing collaboration with SNDL.
Factors that could cause actual results to differ materially from forward-looking statements or that
could affect the operations, performance, development, and results of the Company’s business
include, among other things: delays or denials in obtaining regulatory permits; inability to fulll or
receive additional purchase orders; difculty in maintaining GMP compliance; disruptions in
international markets or trade policies; inability to maintain strategic partnerships; inadequate cash
ow from operations; challenges in accessing debt and equity capital; changes in the regulatory
framework governing cannabis products; competitive pressures; supply and demand uctuations;
and broader economic and market conditions. Any statements that are not historical facts should
be considered forward-looking statements. The forward-looking statements in this news release are
made as of its date, and, except to the extent required by applicable law, the Company assumes no
obligation to update or revise any forward-looking statements made herein or otherwise, whether
due to new information, future events, or otherwise. All forward-looking statements in this news
release are expressly qualied by this cautionary statement.
